AdvaMed Response to Senate HELP Committee Regarding Reauthorization of Pandemic All-Hazards Preparedness Act

AdvaMed, the Medtech Association, joined members the Global Medical Technology Alliance (GMTA) to welcome the recently released World Health Assembly (WHA) resolution on Strengthening Diagnostic Capacity.

This Women’s Health Month, AdvaMed is highlighting new developments in breast cancer screening. 

AdvaMed, the Medtech Association, today called on the Biden Administration to implement a proposal to create a predictable pathway to national Medicare coverage for breakthrough medical technologies. The announcement comes as the U.S. Centers for Medicare & Medicaid Services (CMS) failed to meet its self-imposed April deadline to provide a proposed Transitional Coverage for Emerging Technologies (TCET) rule.

It is easy to take for granted the role medtech plays in our everyday lives. From heart valves, imaging equipment, and pacemakers to continuous glucose monitors, we rely on these technologies to detect, treat, and cure illnesses and injuries of all kinds.

Today, AdvaMed, the medtech association, released the following statement from President and CEO Scott Whitaker on the introduction of the bipartisan Verifying Accurate, Leading-edge IVCT Development (VALID) Act. Introduced in the House of Representatives by Congressman Larry Bucshon (R-Ind.) and Congresswoman Diana DeGette (D-Colo.), the VALID Act modernizes regulatory oversight of in vitro clinical tests (IVCTs) – including in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs).

Today, AdvaMed, the medtech association, applauded the introduction in the House and Senate of the bipartisan Saving Access to Laboratory Services Act (SALSA) by Senators Sherrod Brown (D-OH) and Thom Tillis (R-NC) and Representatives Gus Bilirakis (R-FL), Brian Fitzpatrick (R-PA), Richard Hudson (R-NC), Bill Pascrell (D-NJ), and Scott Peters (D-CA).

Today, AdvaMed, the medtech association, released the following statement from President and CEO Scott Whitaker on the introduction of the bipartisan Ensuring Patient Access to Critical Breakthrough Products Act. The bill, introduced by Representatives Brad Wenstrup (OH-02), Suzan DelBene (WA-01), Gus Bilirakis (FL-12), Tony Cárdenas (CA-29), Blake Moore (UT-01), Terri Sewell (AL-07), Brett Guthrie (KY-02), and Anna Eshoo (CA-16), would streamline Medicare coverage and reimbursement processes for innovative medical technologies.

AdvaMedDx, a division of AdvaMed representing more than 75 manufacturers of innovative in vitro diagnostic (IVD) tests and technologies in the U.S. and abroad, announced today that Thierry Bernard, CEO of QIAGEN, was elected Chair of the AdvaMedDx Board of Directors. He succeeds Norman Schwartz, CEO of Bio-Rad Laboratories.